Silvan Tuerkcan
Stock Analyst at Citizens
(4.31)
# 348
Out of 5,165 analysts
176
Total ratings
47.7%
Success rate
18.28%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $50.09 | +71.69% | 17 | Dec 23, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $35 → $57 | $46.47 | +22.66% | 15 | Dec 11, 2025 | |
| NUVB Nuvation Bio | Maintains: Market Outperform | $8 → $10 | $4.40 | +127.27% | 5 | Nov 20, 2025 | |
| ENGN enGene Holdings | Maintains: Market Outperform | $18 → $21 | $7.25 | +189.66% | 5 | Nov 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Market Outperform | $29 → $21 | $13.48 | +55.79% | 14 | Nov 7, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $6 → $8 | $4.57 | +75.05% | 14 | Nov 5, 2025 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $20 → $22 | $11.75 | +87.23% | 14 | Nov 4, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $1.25 | +380.00% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $11.19 | +203.84% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $34.27 | +31.31% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $50 | $41.83 | +19.53% | 23 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $7.76 | +93.30% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $3.71 | +61.73% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $5.06 | +77.87% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $13.72 | +774.64% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.66 | +924.10% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $2.86 | +39.86% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $10.26 | +104.68% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.08 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.45 | +73.91% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $75.28 | +271.94% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $9.14 | +96.94% | 1 | Jan 26, 2023 |
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $50.09
Upside: +71.69%
Terns Pharmaceuticals
Dec 11, 2025
Maintains: Market Outperform
Price Target: $35 → $57
Current: $46.47
Upside: +22.66%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8 → $10
Current: $4.40
Upside: +127.27%
enGene Holdings
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18 → $21
Current: $7.25
Upside: +189.66%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29 → $21
Current: $13.48
Upside: +55.79%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6 → $8
Current: $4.57
Upside: +75.05%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20 → $22
Current: $11.75
Upside: +87.23%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $1.25
Upside: +380.00%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $11.19
Upside: +203.84%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $34.27
Upside: +31.31%
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $41.83
Upside: +19.53%
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $7.76
Upside: +93.30%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $3.71
Upside: +61.73%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.06
Upside: +77.87%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $13.72
Upside: +774.64%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.66
Upside: +924.10%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $2.86
Upside: +39.86%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $10.26
Upside: +104.68%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.08
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.45
Upside: +73.91%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $75.28
Upside: +271.94%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $9.14
Upside: +96.94%